Cancer immunomodulation using bispecific aptamers

Bispecific Aptamer Chimeras Enable Targeted Protein Degradation on Cell Membranes

(2021) Da Han et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction

(2020) Mengjiao Huang et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Tumor Microenvironment

(2020) Borros Arneth   Medicina-Lithuania

Preclinical murine tumor models: a structural and functional perspective

(2020) Marion V Guerin et al.   eLife

RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs

(2020) Sarah Bajan et al.   Cells

Understanding the Spatial Topology of Artificial Immunological Synapses Assembled in T Cell-Redirecting Strategies: A Major Issue in Cancer Immunotherapy

(2020) Pedro Roda-Navarro et al.   Frontiers in Cell and Developmental Biology

The BiTE (Bispecific T‐Cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types

(2020) Hermann Einsele et al.   CANCER

Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy

(2020) Zhaoying Fu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Small molecules, big impact: 20 years of targeted therapy in oncology

(2020) Philippe L Bedard et al.   LANCET

T cell-engaging therapies — BiTEs and beyond

(2020) Maria-Elisabeth Goebeler et al.   Nature Reviews Clinical Oncology

Aptamers against live targets: Is in vivo SELEX finally coming to edge?

(2020) Mayte Sola et al.   Molecular Therapy-Nucleic Acids

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

(2020) Raju K. Vaddepally et al.   Cancers

Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies

(2020) Steffen Dickopf et al.   Computational and Structural Biotechnology Journal

Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications

(2020) Shuaijian Ni et al.   ACS Applied Materials & Interfaces

Circular Bispecific Aptamer-Mediated Artificial Intercellular Recognition for Targeted T Cell Immunotherapy

(2020) Yu Yang et al.   ACS Nano

Aptamers with tunable affinity enable single‐molecule tracking and localization of membrane receptors on living cancer cells

(2020) Pietro Delcanale et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Aptamer-based technology for radionuclide targeted imaging and therapy: a promising weapon against cancer

(2020) Luca Filippi et al.   Expert Review of Medical Devices

Chemical Modification of Aptamers for Increased Binding Affinity in Diagnostic Applications: Current Status and Future Prospects

(2020) Jan P. Elskens et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Advances in oligonucleotide drug delivery

(2020) Thomas C. Roberts et al.   NATURE REVIEWS DRUG DISCOVERY

Cancer Incidence and Trends

(2020) Melissa C. Hulvat   SURGICAL CLINICS OF NORTH AMERICA

A decade of immune-checkpoint inhibitors in cancer therapy

(2020) Caroline Robert   Nature Communications

New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis

(2020) Iñaki Etxeberria et al.   ESMO Open

Acute statin treatment improves antibody accumulation in EGFR- and PSMA-expressing tumors

(2020) Patricia M.R. Pereira et al.   CLINICAL CANCER RESEARCH

Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy

(2020) Zhaoying Fu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A Homodimeric Aptamer Variant Generated from Ligand-Guided Selection Activates the T Cell Receptor Cluster of Differentiation 3 Complex

(2020) Lina Freage et al.   Molecular Therapy-Nucleic Acids

Recent Advances in Aptamer Discovery and Applications

(2019) Yang Zhang et al.   MOLECULES

Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting

(2019) Zhaoyi Li et al.   MOLECULES

A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4+ T and Natural Killer Cells

(2019) Hampartsoum B. Barsoumian et al.   CANCER RESEARCH

An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer

(2019) Dinh-Toi Chu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Clinical development of targeted and immune based anti-cancer therapies

(2019) N. A. Seebacher et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

(2019) Filipe Martins et al.   Nature Reviews Clinical Oncology

Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors

(2019) Patricia MR Pereira et al.   JOURNAL OF NUCLEAR MEDICINE

Bispecific antibodies: a mechanistic review of the pipeline

(2019) Aran F. Labrijn et al.   NATURE REVIEWS DRUG DISCOVERY

The Neonatal Fc Receptor (FcRn): A Misnomer?

(2019) Michal Pyzik et al.   Frontiers in Immunology

Bispecific Aptamer Induced Artificial Protein-Pairing: A Strategy for Selective Inhibition of Receptor Function

(2019) Liping Wang et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity

(2019) Shengnan Yu et al.   Molecular Cancer

Integrating Ligand-Receptor Interactions and In Vitro Evolution for Streamlined Discovery of Artificial Nucleic Acid Ligands

(2019) Hasan E. Zumrut et al.   Molecular Therapy-Nucleic Acids

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

(2019) Shuang Qin et al.   Molecular Cancer

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

(2019) Satya Das et al.   Journal for ImmunoTherapy of Cancer

Ligand-Guided Selection with Artificially Expanded Genetic Information Systems against TCR-CD3ε

(2019) Hasan Zumrut et al.   BIOCHEMISTRY

Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy

(2019) Zuan-Fu Lim et al.   Journal of Hematology & Oncology

Aptamers Chemistry: Chemical Modifications and Conjugation Strategies

(2019) Fadwa Odeh et al.   MOLECULES

Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment

(2019) Zijun Zhao et al.   Science China-Life Sciences

Aptamer chemistry

(2018) Pascal Röthlisberger et al.   ADVANCED DRUG DELIVERY REVIEWS

Selection of PD1/PD-L1 X-Aptamers

(2018) Hongyu Wang et al.   BIOCHIMIE

RNA-Targeted Therapeutics

(2018) Stanley T. Crooke et al.   Cell Metabolism

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

(2018) Kristian M. Hargadon et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Supramolecularly Engineered Circular Bivalent Aptamer for Enhanced Functional Protein Delivery

(2018) Ying Jiang et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation

(2018) Colin E. Correnti et al.   LEUKEMIA

Targeting the tumour stroma to improve cancer therapy

(2018) Kenneth C. Valkenburg et al.   Nature Reviews Clinical Oncology

The role of osteopontin in the progression of solid organ tumour

(2018) Hailin Zhao et al.   Cell Death & Disease

Modular cell-internalizing aptamer nanostructure enables targeted delivery of large functional RNAs in cancer cell lines

(2018) David Porciani et al.   Nature Communications

Bispecific antibodies: design, therapy, perspectives

(2018) Sergey Sedykh et al.   Drug Design Development and Therapy

Aptamer Therapeutics in Cancer: Current and Future

(2018) Yoshihiro Morita et al.   Cancers

Bioapplications of Cell-SELEX-Generated Aptamers in Cancer Diagnostics, Therapeutics, Theranostics and Biomarker Discovery: A Comprehensive Review

(2018) Xuehui Pang et al.   Cancers

Recent developments in cell-SELEX technology for aptamer selection

(2018) Harleen Kaur   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

An RNA toolbox for cancer immunotherapy

(2018) Fernando Pastor et al.   NATURE REVIEWS DRUG DISCOVERY

Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target

(2018) Jun Wei et al.   JOURNAL OF CLINICAL INVESTIGATION

Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety

(2018) Diego Ellerman   METHODS

Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy

(2018) Patrícia M. R. Pereira et al.   Nature Communications

Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells

(2017) Varun Sasidharan Nair et al.   IMMUNOLOGY AND CELL BIOLOGY

Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine

(2017) Zhenjian Zhuo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes

(2017) Shuaijian Ni et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Circular Bivalent Aptamers Enable in Vivo Stability and Recognition

(2017) Hailan Kuai et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

Emerging functions of the EGFR in cancer

(2017) Sara Sigismund et al.   Molecular Oncology

A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice

(2017) Tal Gefen et al.   MOLECULAR THERAPY

Influence of Molecular size on the clearance of antibody fragments

(2017) Zhe Li et al.   PHARMACEUTICAL RESEARCH

Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)

(2017) Mario Martínez Soldevilla et al.   PLoS One

Permeation of macromolecules into the renal glomerular basement membrane and capture by the tubules

(2017) Marlon G. Lawrence et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis

(2017) Daniel Ajona et al.   Cancer Discovery

Effect of Chemical Modifications on Aptamer Stability in Serum

(2017) Christina Kratschmer et al.   Nucleic Acid Therapeutics

Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth

(2017) Jingying Zheng et al.   Theranostics

A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect

(2017) Bo-Tsang Huang et al.   Molecular Therapy-Nucleic Acids

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses

(2016) Lindsay K. Ward-Kavanagh et al.   IMMUNITY

T cell activation requires force generation

(2016) Kenneth H. Hu et al.   JOURNAL OF CELL BIOLOGY

Aptamers as targeted therapeutics: current potential and challenges

(2016) Jiehua Zhou et al.   NATURE REVIEWS DRUG DISCOVERY

MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells

(2016) Mario Martínez Soldevilla et al.   Oncotarget

A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects

(2016) Wei-Yun Lai et al.   Molecular Therapy-Nucleic Acids

Clinical manufacturing of CAR T cells: foundation of a promising therapy

(2016) Xiuyan Wang et al.   Molecular Therapy-Oncolytics

CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes

(2016) Wei Hseun Yeap et al.   Scientific Reports

2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia

(2015) Mario Martinez Soldevilla et al.   BIOMATERIALS

Global Cancer Incidence and Mortality Rates and Trends--An Update

(2015) L. A. Torre et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer® therapeutics

(2015) Axel Vater et al.   DRUG DISCOVERY TODAY

Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab

(2015) Thomas Köhnke et al.   Journal of Hematology & Oncology

Identifying high-affinity aptamer ligands with defined cross-reactivity using high-throughput guided systematic evolution of ligands by exponential enrichment

(2015) Agata Levay et al.   NUCLEIC ACIDS RESEARCH

Immune evasion in cancer: Mechanistic basis and therapeutic strategies

(2015) Dass S. Vinay et al.   SEMINARS IN CANCER BIOLOGY

Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS

(2015) Miguel F. Sanmamed et al.   SEMINARS IN ONCOLOGY

Aptamers and Their Applications in Nanomedicine

(2015) Hongguang Sun et al.   Small

Identification of TIM3 2’-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy

(2015) Sandra Hervas-Stubbs et al.   Oncotarget

Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers

(2015) Aaron Prodeus et al.   Molecular Therapy-Nucleic Acids

Aptamer-Mediated Codelivery of Doxorubicin and NF-κB Decoy Enhances Chemosensitivity of Pancreatic Tumor Cells

(2015) David Porciani et al.   Molecular Therapy-Nucleic Acids

Co-potentiation of antigen recognition: A mechanism to boost weak T cell responses and provide immunotherapy in vivo

(2015) M. M. Hoffmann et al.   Science Advances

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity

(2015) Todd Bartkowiak et al.   Frontiers in Oncology

Identification and Characterization of an Agonistic Aptamer Against the T Cell Costimulatory Receptor, OX40

(2015) Elizabeth D. Pratico et al.   Nucleic Acid Therapeutics

Accumulation of Dynamic Catch Bonds between TCR and Agonist Peptide-MHC Triggers T Cell Signaling

(2014) Baoyu Liu et al.   CELL

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies

(2014) C. M. Lovly et al.   CLINICAL CANCER RESEARCH

Bispecific T-cell engagers for cancer immunotherapy

(2014) Amelia M Huehls et al.   IMMUNOLOGY AND CELL BIOLOGY

Multidrug Resistance Protein 1 (MRP1, ABCC1), a “Multitasking” ATP-binding Cassette (ABC) Transporter

(2014) Susan P. C. Cole   JOURNAL OF BIOLOGICAL CHEMISTRY

Chemically Modified DNA Aptamers Bind Interleukin-6 with High Affinity and Inhibit Signaling by Blocking Its Interaction with Interleukin-6 Receptor

(2014) Shashi Gupta et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+T Cells

(2014) Keisuke Watanabe et al.   JOURNAL OF IMMUNOLOGY

Aptamer-targeted Antigen Delivery

(2014) Brian C Wengerter et al.   MOLECULAR THERAPY

MUC1: a multifaceted oncoprotein with a key role in cancer progression

(2014) Sritama Nath et al.   TRENDS IN MOLECULAR MEDICINE

The immune synapse clears and excludes molecules above a size threshold

(2014) Adam N. R. Cartwright et al.   Nature Communications

Complex Relationship between Ligand Binding and Dimerization in the Epidermal Growth Factor Receptor

(2014) Nicholas J. Bessman et al.   Cell Reports

Targeting 4-1BB Costimulation to the Tumor Stroma with Bispecific Aptamer Conjugates Enhances the Therapeutic Index of Tumor Immunotherapy

(2014) B. Schrand et al.   Cancer Immunology Research

Targeting Multidrug Resistance Protein 1 (MRP1, ABCC1): Past, Present, and Future

(2013) Susan P.C. Cole   Annual Review of Pharmacology and Toxicology

Cancer heterogeneity: implications for targeted therapeutics

(2013) R Fisher et al.   BRITISH JOURNAL OF CANCER

Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands

(2013) Georges Vauquelin et al.   BRITISH JOURNAL OF PHARMACOLOGY

Hematopoietic Stem and Progenitor Cell Mobilization in Mice and Humans by a First-in-Class Mirror-Image Oligonucleotide Inhibitor of CXCL12

(2013) A Vater et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Novel C5a-neutralizing Mirror-image (l-)Aptamer Prevents Organ Failure and Improves Survival in Experimental Sepsis

(2013) Kai Hoehlig et al.   MOLECULAR THERAPY

Tumour heterogeneity and cancer cell plasticity

(2013) Corbin E. Meacham et al.   NATURE

Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells

(2013) Jiehua Zhou et al.   NUCLEIC ACIDS RESEARCH

EGF receptor trafficking: consequences for signaling and cancer

(2013) Alejandra Tomas et al.   TRENDS IN CELL BIOLOGY

CD28 Aptamers as Powerful Immune Response Modulators

(2013) Fernando Pastor et al.   Molecular Therapy-Nucleic Acids

A Short DNA Aptamer That Recognizes TNFα and Blocks Its Activity in Vitro

(2012) Erik W. Orava et al.   ACS Chemical Biology

In vivo uses of aptamers selected against cell surface biomarkers for therapy and molecular imaging

(2012) Agnes Cibiel et al.   BIOCHIMIE

Aptamer-Mediated Blockade of IL4R  Triggers Apoptosis of MDSCs and Limits Tumor Progression

(2012) F. Roth et al.   CANCER RESEARCH

Interplay between T Cell Receptor Binding Kinetics and the Level of Cognate Peptide Presented by Major Histocompatibility Complexes Governs CD8+T Cell Responsiveness

(2012) Melita Irving et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Isolation and Optimization of Murine IL-10 Receptor Blocking Oligonucleotide Aptamers Using High-throughput Sequencing

(2012) Alexey Berezhnoy et al.   MOLECULAR THERAPY

Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells

(2012) Cindy Meyer et al.   RNA Biology

The intracellular trafficking pathway of transferrin

(2011) Kristine M. Mayle et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Multidrug Efflux Pumps and Cancer Stem Cells: Insights Into Multidrug Resistance and Therapeutic Development

(2011) K Moitra et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Bi-specific Aptamers Mediating Tumor Cell Lysis

(2011) Achim Boltz et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting 4-1BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide Aptamers

(2011) Fernando Pastor et al.   MOLECULAR THERAPY

Antigen Potency and Maximal Efficacy Reveal a Mechanism of Efficient T Cell Activation

(2011) O. Dushek et al.   Science Signaling

Targeted Cell-Cell Interactions by DNA Nanoscaffold-Templated Multivalent Bispecific Aptamers

(2011) Xiaowei Liu et al.   Small

c-MET as a potential therapeutic target and biomarker in cancer

(2011) J. Rafael Sierra et al.   Therapeutic Advances in Medical Oncology

The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung Cancer

(2010) Roy M. Bremnes et al.   Journal of Thoracic Oncology

Industrialization of mAb production technology: The bioprocessing industry at a crossroads

(2010) Brian Kelley   mAbs

The immunogenicity of humanized and fully human antibodies

(2010) Fiona A. Harding et al.   mAbs

Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay

(2010) Fernando Pastor et al.   NATURE

The safety and side effects of monoclonal antibodies

(2010) Trevor T. Hansel et al.   NATURE REVIEWS DRUG DISCOVERY

Assembling OX40 Aptamers on a Molecular Scaffold to Create a Receptor-Activating Aptamer

(2008) Claudia M. Dollins et al.   CHEMISTRY & BIOLOGY

Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice

(2008) James O. McNamara et al.   JOURNAL OF CLINICAL INVESTIGATION

The tumor microenvironment and its role in promoting tumor growth

(2008) T L Whiteside   ONCOGENE

EpCAM expression in normal, non-pathological tissues

(2007) Eva Schmelzer   Frontiers in Bioscience-Landmark

RNA Aptamer-targeted Inhibition of NF-κB Suppresses Non-small Cell Lung Cancer Resistance to Doxorubicin

(2007) Jing Mi et al.   MOLECULAR THERAPY